Olmesartán/Amlodipino Kern Pharma (Olmesartan Medoxomil, Amlodipine)

Olmesartan/Amlodipine is a fixed‑dose combination that addresses elevated blood pressure through two complementary mechanisms. It is employed in the following clinical situations:

• Essential hypertension: provides superior blood pressure reduction when single‑agent therapy is insufficient.
• Hypertension with concomitant cardiovascular risk: helps achieve target pressures in patients with additional risk factors such as dyslipidaemia or smoking.
• Hypertension in patients requiring once‑daily dosing: simplifies regimen adherence by combining an ARB and a calcium‑channel blocker.

• Olmesartan Medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. The dual action reduces peripheral vascular resistance and lowers systemic blood pressure more effectively than either component alone.

Common Side Effects

• Dizziness: mild to moderate light‑headedness, especially after the first dose.
• Headache: transient tension‑type headache.
• Peripheral edema: swelling of ankles or lower legs.
• Flushing: warm sensation and reddening of skin.
• Fatigue: general tiredness without specific cause.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Myocardial infarction: chest pain indicative of heart attack.
• Acute renal impairment: sudden decrease in kidney function.
• Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider the following precautions:

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: adjust therapy in patients with impaired kidney function.
• Hepatic status: use cautiously in severe liver disease.
• Electrolyte balance: monitor potassium and sodium levels, especially with concomitant diuretics.
• Pregnancy and lactation: avoid use during pregnancy; discontinue if pregnancy is confirmed.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Major Interactions (Avoid)

• ACE inhibitors or aliskiren: combined use may increase risk of hyperkalemia and renal dysfunction.
• Potassium‑sparing diuretics: additive effect on serum potassium leading to hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may raise amlodipine concentrations and cause hypotension.
• NSAIDs: can blunt antihypertensive effect and affect renal function.
• Dual renin‑angiotensin system blockade: heightened risk of adverse renal outcomes.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (beta‑blockers, diuretics): may require dose adjustment to prevent excessive blood pressure drop.
• CYP3A4 inducers (rifampin, carbamazepine): may reduce amlodipine levels, diminishing efficacy.
• Lithium: concurrent use may increase lithium levels, necessitating monitoring.